Heron Therapeutics | HRTX - Себестоимость





Себестоимость Изменить Дата
ALKERMES USD 73.25M 27.04M 2026-03
Alnylam Pharmaceuticals USD 211.12M 56.6M 2026-03
Amarin USD 26.05M 1.41M 2025-12
ANI Pharmaceuticals USD 114.5M 8.38M 2026-03
Anika Therapeutics USD 11.44M 797K 2025-12
Eisai JPY 52.02B 931M 2026-03
Emergent BioSolutions USD 381.2M 226.1M 2023-06
Esperion Therapeutics USD 27.85M 13.43M 2025-12
GlaxoSmithKline GBP 1.88B 736M 2026-03
Heron Therapeutics USD 11.12M 795K 2025-12
Insmed USD 49.5M 3.34M 2026-03
Ligand Pharmaceuticals USD 11.37M 8.38M 2026-03
Merck USD 2.94B 380M 2026-03
Nektar Therapeutics USD 4.43M 5.3M 2024-09
Neurocrine Biosciences USD 13.8M 3.8M 2026-03
Omeros USD 33.16M 18.52M 2024-06
Pacira USD 50.74M 3.89M 2026-03
Regeneron Pharmaceuticals USD 669.4M 84.8M 2026-03
Roche Holding CHF 8.48B 4.61B 2025-12
Sangamo BioSciences 2.42M 1.11M 2024-06
Ultragenyx Pharmaceutical USD 30M 1000K 2026-03
Veracyte USD 38.49M 794K 2026-03
Vertex Pharmaceuticals USD 392.8M 73.2M 2026-03